ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) have been assigned an average recommendation of "Buy" from the eight analysts that are covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $8.00.

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a report on Friday, June 27th. Evercore ISI reaffirmed an "outperform" rating on shares of ProQR Therapeutics in a research note on Friday, July 11th. Oppenheimer reduced their price objective on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. JMP Securities reissued a "market outperform" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research note on Friday, June 27th. Finally, Chardan Capital restated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, August 8th.

ProQR Therapeutics Stock Up 3.4%

Shares of NASDAQ PRQR opened at $2.12 on Tuesday. The stock's 50 day moving average price is $2.11 and its two-hundred day moving average price is $1.87. The stock has a market capitalization of $223.05 million, a P/E ratio of -4.61 and a beta of 0.43. ProQR Therapeutics has a 52-week low of $1.07 and a 52-week high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). The company had revenue of $4.33 million for the quarter, compared to analyst estimates of $5.01 million. ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%. On average, analysts anticipate that ProQR Therapeutics will post -0.31 EPS for the current year.

Institutional Trading of ProQR Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of PRQR. Adage Capital Partners GP L.L.C. increased its position in ProQR Therapeutics by 164.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock worth $25,446,000 after buying an additional 5,976,813 shares during the last quarter. Woodline Partners LP acquired a new position in ProQR Therapeutics during the fourth quarter worth $9,426,000. Affinity Asset Advisors LLC increased its position in ProQR Therapeutics by 6.5% during the second quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company's stock worth $7,139,000 after buying an additional 215,000 shares during the last quarter. Millennium Management LLC increased its position in ProQR Therapeutics by 1,864.4% during the fourth quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock worth $7,492,000 after buying an additional 2,683,351 shares during the last quarter. Finally, Sio Capital Management LLC increased its position in ProQR Therapeutics by 1.0% during the second quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company's stock worth $4,233,000 after buying an additional 20,546 shares during the last quarter. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.